<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04363359</url>
  </required_header>
  <id_info>
    <org_study_id>CXSL1900048-Ⅰ+Ⅱ</org_study_id>
    <nct_id>NCT04363359</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Quadrivalent Influenza Virus Split Vaccine</brief_title>
  <official_title>Immunogenicity and Safety of Quadrivalent Influenza Vaccine In 6 to 35 Months Population: a Randomized, Double-blind, Parallel-group Ⅱ Phase of Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Institute Of Biological Products</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Institute Of Biological Products</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the immunogenicity and safety of 2 doses of quadrivalent influenza virus split
      vaccine in healthy population aged 6-35 month., so as to provide a data support for phase III
      clinical trials.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>seroconversion rate of HI antibodies</measure>
    <time_frame>56 days</time_frame>
    <description>28 days after receiving two doses of vaccine in subjects aged 6-35 months, seroconversion rate of HI antibodies against any subtype of influenza virus in each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>seroprotection rate of HI antibodies</measure>
    <time_frame>56 days</time_frame>
    <description>28 days after receiving two doses of vaccine in subjects aged 6-35 months, seroprotection rate of HI antibodies against any subtype of influenza virus in each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMT and GMI of HI antibodies</measure>
    <time_frame>56 days</time_frame>
    <description>28 days after receiving two doses of vaccine in subjects aged 6-35 months, GMT and GMI of HI antibodies against any subtype of influenza virus in each group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reactogenicity Events</measure>
    <time_frame>30 days and 6 months</time_frame>
    <description>The proportion of all adverse reactions/events in each group through 30 days after the second dose.
The proportion of serious adverse events (SAE) within 6 months after inoculation in each group.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1980</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Quadrivalent influenza vaccine HD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive two injections of 0.5 mL quadrivalent influenza vaccine at Day 0 and 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quadrivalent influenza vaccine LD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive two injections of 0.25 mL quadrivalent influenza vaccine at Day 0 and 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trivalent influenza vaccine Victoria</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to receive two injections of 0.25 mL trivalent influenza vaccine containing B/Victoria strain at Day 0 and 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trivalent influenza vaccine Yamagata</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to receive two injections of 0.25 mL trivalent influenza vaccine containing B/Yamagata strain at Day 0 and 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>0.5ml Quadrivalent influenza vaccine</intervention_name>
    <description>The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains</description>
    <arm_group_label>Quadrivalent influenza vaccine HD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>0.25ml Quadrivalent influenza vaccine</intervention_name>
    <description>The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains</description>
    <arm_group_label>Quadrivalent influenza vaccine LD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>0.25ml Trivalent influenza vaccine(B/V)</intervention_name>
    <description>The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Victoria strains</description>
    <arm_group_label>Trivalent influenza vaccine Victoria</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>0.25ml Trivalent influenza vaccine(B/Y)</intervention_name>
    <description>The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Yamagata strains</description>
    <arm_group_label>Trivalent influenza vaccine Yamagata</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy infants aged 6-35 months.

          -  Volunteer legal guardian or client informed consent, voluntarily participate in and
             sign informed consent.

          -  The volunteer legal guardian or client has the ability (non-illiterate) to understand
             the study procedures, to use a thermometer, scale, and fill in a diary card as
             required, and be able to complete the clinical study in compliance with the clinical
             trial protocol.

        Exclusion Criteria:

          -  The underarm body temperature on the day of enrollment was &gt; 37.0℃.

          -  Have been suffering from influenza within the previous 3 months (confirmed by either
             clinical, serological or microbiological methods).

          -  Any previous influenza vaccination (registered or experimental) within 6 months or any
             planned influenza vaccination during the study period.

          -  Allergic to any component of the vaccine, a history of allergic reactions to eggs or
             gentamicin sulfate.

          -  A history of severe allergy to any vaccine or drug.

          -  Preterm birth (delivered before 37 weeks of gestation), low birth weight baby (birth
             weight &lt; 2300g for girls, &lt;2500g for boys).

          -  Dystocia, asphyxia rescue, nervous system damage history;

          -  Congenital malformations or developmental disorders, genetic defects, severe
             malnutrition, etc.

          -  Acute illness, severe chronic illness or acute attack of chronic disease on the day of
             vaccination;

          -  A history of live attenuated vaccination within 14 days prior to vaccination and a
             history of other vaccinations within 7 days prior to vaccination;

          -  Patients who received immunoenhancement or inhibitor therapy within 3 months
             (continued oral or intravenous administration for more than 14 days);

          -  Congenital or acquired immune deficiency, HIV infection, lymphoma, leukemia or other
             autoimmune diseases;

          -  History of asthma, past two years of instability requiring emergency treatment,
             hospitalization, intubation, oral or intravenous administration of corticosteroids;

          -  Have received blood or blood-related products;

          -  A history of convulsion, epilepsy, encephalopathy, guillain-barre syndrome, a history
             of mental illness or a family history;

          -  A history of abnormal coagulation function (such as coagulation factor deficiency,
             coagulation disease);

          -  Planning to relocate before the end of the study or to leave for an extended -period
             during the scheduled study visit;

          -  Participating in or planning to participate in other clinical trials in the near
             future;

          -  The investigators determined that any conditions were inappropriate to participate in
             the clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shilei Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Institute Of Biological Products</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenqing Chai</last_name>
    <phone>86-021-62750096</phone>
    <email>chaiwenqing@sinopharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan Provincial Center for Disease Control and Prevention</name>
      <address>
        <city>Shangqiu</city>
        <state>Henan</state>
        <zip>450016</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xia Sheng-Li, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT04363359/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

